Brief: Citius Pharmaceuticals Advances Efforts To Spin Off Oncology Asset
30/03/2023 15:18
March 30 (Reuters) - Citius Pharmaceuticals Inc
CTXR.O :
* CITIUS PHARMACEUTICALS ADVANCES EFFORTS TO SPIN OFF
ONCOLOGY
ASSET, I/ONTAK, INTO A STANDALONE PUBLIC COMPANY
* CITIUS PHARMACEUTICALS INC - FDA IS CURRENTLY REVIEWING A
BLA
FOR I/ONTAK AND HAS SET A TARGETED DECISION DATE (PDUFA) OF JULY
28, 2023
Source text for Eikon: ID:nPnbX8mcGa
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules